Last $76.93 USD
Change Today +0.18 / 0.23%
Volume 1.5M
DVA On Other Exchanges
Symbol
Exchange
New York
As of 8:04 PM 03/5/15 All times are local (Market data is delayed by at least 15 minutes).

davita healthcare partners i (DVA) Key Developments

DaVita HealthCare Partners Inc. and New York Achievement First Announces Ongoing Partnership to Grow Achievement First Organizational Culture

DaVita HealthCare Partners Inc. and New York Achievement First announced an ongoing partnership to help Achievement First grow its organizational culture. The first-of-its-kind program for New York kicked off in May 2014 when Dacia M. Toll, co-CEO and president for Achievement First, and Kent Thiry, co-chairman and CEO of DaVita Healthcare Partners, came together to create an intentional culture that would help enhance the relationship between teachers and parents within the school district. DaVita HealthCare Partners helped create a two-day program that increased stakeholder engagement, better connected parents to the school culture, and established commitments that participants could bring to life at home and at school. DaVita HealthCare Partners continues to support Achievement First with strategic advice as they determine how best to scale the program for future offerings.

DaVita Healthcare Partners Inc.'s DaVita Kidney Care Appoints Mahesh Krishnan as International Chief Medical Officer and Group Vice President of Research and Development

DaVita Kidney Care, a division of DaVita HealthCare Partners Inc. announced that Mahesh Krishnan, M.D., MPH, MBA, FASN, will serve as the company's international chief medical officer (CMO) and group vice president of research and development to implement global clinical initiatives. Krishnan previously served as DaVita Kidney Care's vice president of clinical research, innovation and public policy. Prior to joining DaVita Kidney Care in 2009, Krishnan worked in various nephrology leadership positions with Amgen, heading up global health economics and outcomes research for nephrology. He also was responsible for overseeing the Dialysis Outcomes Practice Pattern Study.

DaVita Healthcare Partners Inc. Reports Unaudited Consolidated Earnings Results for the Fourth Quarter and Year Ended December 31, 2014; Provides Earnings Guidance for the Fiscal Year 2015

DaVita HealthCare Partners Inc. reported unaudited consolidated earnings results for the fourth quarter and year ended December 31, 2014. For the quarter, the company reported total net revenue of $3,328,017,000 against $3,063,209,000 a year ago. Operating income was $452,085,000 against $484,179,000 a year ago. Income from continuing operations before income taxes was $354,365,000 against $380,020,000 a year ago. Income from continuing operations was $250,388,000 or $0.96 diluted per share against $244,273,000 or $0.99 diluted per share a year ago. Net income attributable to the company was $208,020,000 or $0.96 diluted per share against $212,278,000 or $0.99 diluted per share a year ago. Free cash flow was $197 million. Adjusted income from continuing operations attributable to the company, excluding the amortization of intangible assets associated with acquisitions, net of tax impacts, was $236 million or $1.09 per share. For the year, the company reported total net revenue of $12,795,106,000 against $11,764,050,000 a year ago. Operating income was $1,815,141,000 against $1,550,134,000 a year ago. Income from continuing operations before income taxes was $1,309,673,000 against $1,124,978,000 a year ago. Income from continuing operations was $863,330,000 or $3.33 diluted per share against $743,965,000 or $2.89 diluted per share a year ago. Net income attributable to the company was $723,114,000 or $3.33 diluted per share against $633,446,000 or $2.95 diluted per share a year ago. Net cash provided by operating activities $1,459,407,000 against $1,773,341,000 a year ago. Additions of property and equipment, net were $641,330,000 against $617,597,000 a year ago. Purchase of intangible assets was $1,018,000 against $2,391,000 a year ago. Adjusted income from continuing operations attributable to the company, excluding a loss contingency reserve and debt refinancing charges was $792 million or $3.64 per share. Adjusted income from continuing operations attributable to the company, excluding a loss contingency reserve and a contingent earn-out obligation adjustment, was $818 million or $3.81 per share. Free cash flow was $1.045 billion. Adjusted operating income excluding a loss contingency reserve was $1.832 billion. Adjusted operating income for the year ended December 31, 2013, excluding a loss contingency reserve, an adjustment to reduce a tax asset associated with the HCP acquisition escrow provisions and a contingent earn-out obligation adjustment, was $1.898 billion. Adjusted income from continuing operations attributable to the company for the year, excluding the amortization of intangible assets associated with acquisitions, net of tax impacts, was $896 million and adjusted diluted income from continuing operations per share was $4.13. In addition, adjusted income from continuing operations and adjusted diluted income from continuing operations per share for the year ended December 31, 2014 excluded a loss contingency reserve and debt refinancing charges. Consolidated net debt as on December 31, 2014 was $7,425,825,000. The company currently expects 2015 effective tax rate attributable to be approximately 39.5% to 40.5%. The company still expects consolidated operating income for 2015 to be in the range of $1.750 billion to $1.900 billion. The company expects operating income for Kidney Care for 2015 to be in the range of $1.525 billion to $1.625 billion. The company expects operating income for HCP for 2015 to be in the range of $225 million to $275 million and expects consolidated operating cash flow for 2015 to be in the range of $1.500 billion to $1.700 billion.

Centura Health and DaVita HealthCare Partners Introduce FullWell

Centura Health and DaVita HealthCare Partners unveiled FullWell, the brand name of the two partners' recently announced joint venture, a company that aims to bring greater value to health care and lower costs for consumers in Colorado and Kansas. FullWell, when launched, will combine the expertise of the region's leading health care system with a nationally recognized leader in physician-centric coordinated care to transform the way health care is delivered. Specifically, FullWell will equip providers of Colorado Health Neighborhoods (CHN), the Centura Health physician-led network, with immediate access to data analytics. This data delivers critical information to support early identification of patients at high risk for chronic health conditions and real-time feedback on the efficacy of treatments consumers may be receiving. FullWell will employ tools to help engage, inform and empower consumers to actively manage and maintain their health through the trusting relationship with their provider. Additionally, FullWell brings access to improved information systems, team-based care coordination and financial incentives for better health outcomes to providers.

Davita Healthcare Partners Inc. to Settle Shareholder Lawsuits Stemming from Federal Kickback Settlement

DaVita Healthcare Partners Inc., after agreeing already to pay the federal government $389 million to settle allegations that it violated an anti-kickback law announced that it will pay out roughly $7.3 million more to settle lawsuits from shareholders regarding that episode. The company filed forms with the U.S. Securities Exchange Commission indicating that it plans to settle two derivative claims lawsuits brought by shareholders claiming that company officials breached their fiduciary duties when they entered into joint ventures with doctors who would refer patients to DaVita dialysis clinics. Under the proposed settlement, the lead plaintiff, Haverhill Retirement System, would receive an incentive fee for $10,000 and attorneys for the plaintiffs would receive $7.3 million.

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
DVA:US $76.93 USD +0.18

DVA Competitors

Market data is delayed at least 15 minutes.

Company Last Change
Apollo Medical Holdings Inc $0.40 USD 0.00
Fresenius Medical Care AG & Co KGaA €74.86 EUR +0.466
Fresenius SE & Co KGaA €51.88 EUR +0.168
IPC Healthcare Inc $43.12 USD -0.28
Team Health Holdings Inc $58.26 USD 0.00
View Industry Companies
 

Industry Analysis

DVA

Industry Average

Valuation DVA Industry Range
Price/Earnings 23.0x
Price/Sales 1.3x
Price/Book 3.2x
Price/Cash Flow 12.6x
TEV/Sales 0.4x
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact DAVITA HEALTHCARE PARTNERS I, please visit . Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.